Actively Recruiting

Phase Not Applicable
Age: 6Years - 13Years
All Genders
NCT07020936

AIDANET Pediatrics

Led by Mark D. DeBoer, MD, MSc., MCR · Updated on 2025-12-10

36

Participants Needed

3

Research Sites

36 weeks

Total Duration

On this page

Sponsors

M

Mark D. DeBoer, MD, MSc., MCR

Lead Sponsor

T

Tandem Diabetes Care, Inc.

Collaborating Sponsor

AI-Summary

What this Trial Is About

AIDANET algorithm with smart-phone based control system (study smart phone), specifically modified Tandem insulin system (study insulin pump), and Dexcom G6 CGM (study CGM).

CONDITIONS

Official Title

AIDANET Pediatrics

Who Can Participate

Age: 6Years - 13Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 6 to 13 years old at time of consent
  • Clinical diagnosis of type 1 diabetes for at least one year
  • Using an insulin pump for at least three months (any type)
  • Using insulin for at least six months
  • Willing to use lispro or aspart insulin in the pump during the study
  • Currently using a Dexcom G6 or G7 continuous glucose monitor
  • Has a parent or guardian knowledgeable about severe hypoglycemia emergency procedures who lives with the participant
  • Not currently pregnant or breastfeeding
  • If able to become pregnant, agrees to use contraception and has a negative pregnancy test; will discontinue if pregnancy occurs or is planned during the study
  • Willing to use the study's full closed-loop system (CGM, pump, and phone) during the study
  • Willing not to start new non-insulin glucose-lowering medications during the trial
  • Willing to participate in all study procedures including supervised hotel sessions and to consume about three unannounced meals per day during these sessions
  • Has internet access at home and agrees to upload data as needed
  • Investigator believes participant can operate study devices and follow the protocol
  • Proficient in reading and writing English
Not Eligible

You will not qualify if you...

  • Plans to start new non-insulin glucose-lowering medications during the study (e.g., GLP-1 receptor agonists, Symlin, DPP-4 inhibitors, sulfonylureas)
  • Currently using SGLT-2 or SGLT-1/2 inhibitors
  • Has hemophilia or another bleeding disorder
  • History of severe low blood sugar events with seizure or unconsciousness in the past 6 months
  • History of diabetic ketoacidosis in the past 6 months
  • Chronic kidney disease (Stage 4 or unstable Stage 3b) or on dialysis
  • History of adrenal insufficiency
  • Currently treated for a seizure disorder
  • Under-treated hypothyroidism or hyperthyroidism
  • Coronary artery disease or heart condition preventing moderate exercise
  • Use of oral or injectable steroids within 4 weeks before enrollment
  • Planned surgery during the study period
  • Known ongoing adhesive intolerance not well managed
  • Any condition that may put participant or study at risk as judged by the investigator
  • Participation in another interventional trial at enrollment
  • Participant has a direct supervisor involved in the study conduct

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

University of California San Francisco

San Francisco, California, United States, 94158

Actively Recruiting

2

Barbara Davis Center, University of Colorado

Aurora, Colorado, United States, 80045

Actively Recruiting

3

University of Virginia Center for Diabetes Technology

Charlottesville, Virginia, United States, 22903

Actively Recruiting

Loading map...

Research Team

L

Lianna Smith

CONTACT

S

Sara Prince, RN

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here